Endogenous lipoproteins impact the response to endotoxin in humans

Critical Care Medicine

Volumn 30, Issue 1, 2002, Pages 23-31

  Harris, Hobart W ^a,b   Johnson, Jennifer A ^a   Wigmore, Stephen J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Acute phase response; Chylomicrons; Cytokines; Endotoxin; Endotoxins; Gram negative infections; Lipopolysaccharide binding protein; Lipoproteins; Sepsis; Very low density lipoproteins

Indexed keywords

ENDOTOXIN; LIPOPOLYSACCHARIDE; LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET RESTRICTION; GRAM NEGATIVE SEPSIS; HUMAN; HUMAN EXPERIMENT; HYPERTRIGLYCERIDEMIA; IMMUNE RESPONSE; NORMAL HUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL;

EID: 0036152459     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200201000-00004     Document Type: Article

References (46)

1. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin
2. Catalytic properties of lipopolysaccharide (LPS) binding protein. Transfer of LPS to soluble CD14
3. Lipopolysaccharide-binding protein and soluble CD14 transfer lipopolysaccharide to phospholipid bilayers: Preferential interaction with particular classes of lipid
4. Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface
5. Lipopolysaccharide-binding protein and phospholipid transfer protein release lipopolysaccharides from Gram-negative bacterial membranes
6. Bacterial lipopolysaccharide binds and stimulates cytokine-producing cells before neutralization by endogenous lipoproteins can occur
7. Serum protein-bound carbohydrates and lipids in cholera
8. Serum lipids in infection
9. Sepsis and fat metabolism
10. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice
11. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death
12. The protective effect of serum lipoproteins against bacterial lipopolysaccharide
13. Chylomicrons alter the hepatic distribution and cellular response to endotoxin in rats
14. Effect of hypertriglyceridemia on endotoxin responsiveness in humans
15. Diet-induced protection against lipopolysaccharide includes increased hepatic NO production
16. Chylomicron-bound endotoxin inhibits hepatocellular nitric oxide production by inhibiting nuclear factor kB activation in rats
17. The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum
18. New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides
19. A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits
20. In vivo protection against endotoxin by plasma high density lipoprotein
21. Reconstituted high density lipoprotein inhibits physiologic and tumor necrosis factor alpha responses to lipopolysaccharide in rabbits
22. Reconstituted high-density lipoprotein neutralizes Gram-negative bacterial lipopolysaccharides in human whole blood
23. Triglyceride-rich lipoproteins improve survival when given after endotoxin in rats
24. Triglyceride-rich lipoproteins prevent septic death in rats
25. Role for circulating lipoproteins in protection from endotoxin toxicity
26. Protective effects of reconstituted high-density lipoprotein in rabbit Gram-negative bacteremia models
27. Reconstituted high-density lipoprotein reduces LPS-stimulated TNF alpha
28. Effects of reconstituted high-density lipoprotein in persistent Gram-negative bacteremia
29. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia
30. Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats in vivo
31. Detection of circulating tumor necrosis factor after endotoxin administration
32. Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes
33. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis
34. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: Relation to severity of liver disturbance
35. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock
36. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease
37. Acute-phase proteins and other systemic responses to inflammation
38. Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability-increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis
39. The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome
40. Fat emulsion infusion potentiates coagulation activation during human endotoxemia
41. Effects of intravenous infusions of commercial fat emulsions (Intralipid 10 or 20%) on rat plasma lipoproteins: Phospholipids in excess are the main precursors of lipoprotein-X-like particles
42. Lipid composition and structure of commercial parenteral emulsions
43. Intravenous lipid emulsions: Removal mechanisms as compared to chylomicrons
44. Catabolism of lipoprotein-X induced by infusion of 10% fat emulsion
45. Endogenous triglyceride-rich lipoproteins accumulate in rat plasma when competing with a chylomicron-like triglyceride emulsion for a common lipolytic pathway
46. Intravenous intralipid 10% vs. 20%, hyperlipidemia, and increase in lipoprotein X in humans